Canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, and sotagliflozin are the five therapeutic agents of a class of SGLT2 inhibitors that have been approved to date by the FDA; they are now being considered as a second-line therapy for the management of T2DM [3,9,196,197]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.